These shifts in metabolism are often global across the brain, e.g., in a meta-analysis, the conditions of eyes closed versus open, sevoflurane and desflurane anesthesia, and comas of varying levels all demonstrated a global shift, whereas only congenitally blind versus sighted demonstrated localized changes [61]
GST overexpression and polymorphisms are seen in several cancers as well as other diseases, and have been implicated in resistance to chemotherapy 2,3
Goldman Sachs projects the oral GLP-1 market will reach $22 billion by 2030, with orforglipron potentially capturing the larger share
This possibility is an exciting avenue for further research and possible novel treatment targets
Those totals are almost certainly undercounts, because most state-licensed compounding pharmacies are not required to submit reports